Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Simcere Plans to Triple Headcount in New R&D Facility

publication date: Aug 3, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Simcere Pharmaceutical will increase its R&D staff to 1,000 in the next three or four years, up from its present headcount of 300. The company recently announced it would build a new R&D center in Beijing's Zhongguancun Innovation Park, where it recently bought rights to 65,300 square meters of land. The company is headquartered in Nanjing, but Simcere said it wanted to access Beijing’s talent pool. The company says it needs R&D to increase its product portfolio. More details....

Stock Symbol: (NYSE: SCR)     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...